Live Breaking News & Updates on ஆராய்ச்சி க்கு ப்ரெவெந்ஶந்|Page 4
Stay updated with breaking news from ஆராய்ச்சி க்கு ப்ரெவெந்ஶந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Home page of the Jilinde PrEP programme in Kenya This year s HIV Research for Prevention (HIVR4P) virtual conference featured a large number of sessions examining PrEP usage and discontinuation rates among a variety of users, especially in Africa. Many of the presentations looked at factors that worked as incentives to keep taking PrEP. There is interest in this because, despite higher initiation rates in a larger number of countries than ever before, the retention rates (also called persistence rates) of people in PrEP programmes in the region remain very low. Kate Segal from AVAC gave a summary of where the world is at in terms of PrEP initiations, as reported by Krishen Samuel here. In sub-Saharan Africa, over half a million people have started PrEP since 2016 and initiations overtook those in North America during the second half of 2018. ....
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking I agree you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our Cookie Settings . Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cookiesI agree Cookie Settings Cookie Settings This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this websit ....
Phase 1 clinical trial of novel HIV vaccine approach shows promising results A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well. With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens. ....
Phase 1 Clinical Trial Confirms HIV Vaccine Approach by Angela Mohan on February 4, 2021 at 11:12 AM Phase 1 clinical trial testing a novel vaccine against HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well, says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI s Neutralizing Antibody Center, whose laboratory developed the vaccine. ....